Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology. The company’s lead drug candidate includes IMO-8400, which is in Phase 1/2 clinical trials for the treatment of Waldenström’s Macroglobulinemia, diffuse large B-cell lymphoma, and Duchenne muscular dystrophy, as well as in Phase 2 clinical trial for the treatment of dermatomyositis. Its products also comprise IMO-9200, a drug candidate in Phase 1 clinical trial for use in selected autoimmune disease indications; and IMO-2055/IMO-2125 that are in Phase 1/2 clinical trials for applications as immune therapies for the treatment of cancer. In addition, the company is developing GSOs to turn off the messenger RNA associated with disease causing genes. It has license and research collaboration agreement with Merck & Co. to research, develop, and commercialize vaccine adjuvants containing TLR7, TLR8, and TLR9 agonists in the fields of cancer, infectious diseases, and Alzheimer’s disease; an agreement with Abbott Molecular Inc. for the development of an in vitro companion diagnostic test; a collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its third generation antisense platform for the treatment of selected targets in renal disease. Idera Pharmaceuticals, Inc. was founded in 1989 and is based in Cambridge, Massachusetts.